Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news

Methotrexate toxicity from unintentional dosing errors: calls to a poison center and death descriptions - Thompson JA, Love JS, Hendrickson RG.
BACKGROUND: Methotrexate is a folate analog prescribed for varying disease with weekly administration as opposed to daily. Dosing errors can prove clinically significant and sometimes fatal. METHODS: We performed a retrospective poison center revie... (Source: SafetyLit)
Source: SafetyLit - November 16, 2021 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Psoriatic Arthritis Management: From Intramuscular Gold to Biologics Psoriatic Arthritis Management: From Intramuscular Gold to Biologics
Phillip J. Mease, MD, reflects on the development of therapeutics for psoriatic arthritis, from intramuscular gold and oral methotrexate in former decades, to the recent use of biologics.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 11, 2021 Category: Consumer Health News Tags: Rheumatology MDAngle Source Type: news

Risk for VTE in RA May Be Higher With MTX vs Hydroxychloroquine Risk for VTE in RA May Be Higher With MTX vs Hydroxychloroquine
The significance of higher risk for VTE seen among patients with RA who took methotrexate compared with hydroxychloroquine is unclear without researching the relationships between the drugs and VTE.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - November 4, 2021 Category: Rheumatology Tags: Rheumatology News Source Type: news

Methotrexate Cannot Maintain TNFi-Induced Remission in pSpA Methotrexate Cannot Maintain TNFi-Induced Remission in pSpA
Is the addition of methotrexate an effective step-down strategy in patients who achieved clinical remission with TNF inhibitors?Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 2, 2021 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

New Comprehensive Phase 3 Data Show First-in-Class TREMFYA ® (guselkumab) Provided Durable Improvements in Measures of Psoriatic Arthritis (PsA) Disease Activity Through Two Years
SPRING HOUSE, PENNSYLVANIA, November 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced comprehensive efficacy and safety data from the DISCOVER–2 trial of TREMFYA® (guselkumab) were published in Arthritis & Rheumatology, representing the final results of the first two-year clinical trial investigating a selective interleukin (IL)-23 inhibitor therapy in active psoriatic arthritis (PsA).1 Results show a majority of TREMFYA-treated biologic-naïve adult patients with active PsA achieved improvements in joint signs and symptoms (American College of Rheumatology [AC...
Source: Johnson and Johnson - November 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately t...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits Application Seeking U.S. FDA Approval of STELARA ® (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, October 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking expanded approval of STELARA® (ustekinumab) to treat pediatric patients ages 5 years and older with juvenile psoriatic arthritis (jPsA).The filing is supported by extrapolation of data from nine studies across both adult trials in active PsA and adult and pediatric studies in moderate to severe plaque psoriasis, totaling 3,997 patients evaluated across these closely associa...
Source: Johnson and Johnson - October 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Analysis Presented by Janssen at United European Gastroenterology Week (UEGW) Demonstrates Long-Term Safety Profile for STELARA ® (ustekinumab) in Older Patients Across Approved Indications
SPRING HOUSE, PENNSYLVANIA, October 4, 2021 – Today, the Janssen Pharmaceutical Companies of Johnson & Johnson announced a new analysis of STELARA® (ustekinumab) pooled safety data from 13 clinical studies across approved indications, showing rates of key safety events among adults 60 years and older treated with STELARA for up to five yearsa were similar to rates observed with placebo during the control phase of these trials.1,b Approved indications included adults with moderately to severely active Crohn’s disease (CD), moderately to severely active ulcerative colitis (UC), moderate to severe plaque p...
Source: Johnson and Johnson - October 4, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Mayo Clinic Q and A: Treating a rare skin disorder known as morphea
DEAR MAYO CLINIC: About six months ago, a large, white dent appeared on my left buttock. I went to a dermatologist who performed a biopsy. I was diagnosed with morphea and prescribed methotrexate. The doctor said the condition is not systemic, but that the drug could prevent future skin lesions and possibly cure the morphea. Can you share more about the condition, and the risks and benefits of the treatment? ANSWER: Morphea, which is a rare skin… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 30, 2021 Category: Databases & Libraries Source Type: news

Five Biologics Perform Strongly in Children With Psoriasis Five Biologics Perform Strongly in Children With Psoriasis
Biologic therapy for children with psoriasis was associated with a significantly increased likelihood of achieving PASI 75 or PASI 100, compared with placebo or methotrexate.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - September 28, 2021 Category: Dermatology Tags: Dermatology News Source Type: news

Does Methotrexate Influence Covid-19 Infection? Does Methotrexate Influence Covid-19 Infection?
Might treatment with methotrexate help lower the risk for developing COVID-19? A new study examines the possible protective effects of this drug.Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 26, 2021 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Patients on Methotrexate Show T-Cell Response to Pfizer Vaccine Patients on Methotrexate Show T-Cell Response to Pfizer Vaccine
Despite poor antibody response to the mRNA COVID-19 vaccine, cellular immunity was generated in patients taking methotrexate, new research shows.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - July 12, 2021 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news

STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial
SPRING HOUSE, PENNSYLVANIA, July 9, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new three-year data from the long-term extension (LTE) of the STELARA® (ustekinumab) Phase 3 UNIFI study. The data demonstrated the majority (55.2 percent) of adult patients with moderately to severely active ulcerative colitis (UC) who initially responded to treatment with STELARA sustained symptomatic remissiona rates at nearly three years (week 152).1 Furthermore, a majority (96.4 percent) of the patients in symptomatic remissiona at week 152 were corticosteroid-free. These data are being pr...
Source: Johnson and Johnson - July 9, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Study Estimates Incidence of Dupilumab-Related Conjunctivitis Study Estimates Incidence of Dupilumab-Related Conjunctivitis
The overall incidence rate of conjunctivitis within 6 months of starting treatment was 6.6% in dupilumab users, compared with 3.3% in methotrexate users.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - June 18, 2021 Category: Drugs & Pharmacology Tags: Dermatology News Source Type: news

Patients Taking Anti-Inflammatory Drugs Respond Less Well to COVID-19 Vaccine
(NYU Langone Health / NYU Grossman School of Medicine) One-quarter of people who take the drug methotrexate for common immune system disorders -- from rheumatoid arthritis to multiple sclerosis -- mount a weaker immune response to a COVID-19 vaccine, a new study shows. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 2, 2021 Category: Infectious Diseases Source Type: news

Methotrexate May Impair Immune Response to mRNA COVID-19 Vaccine
WEDNESDAY, May 26, 2021 -- Patients with immune-mediated inflammatory diseases (IMIDs) receiving background methotrexate have worse humoral and cellular immunogenicity to mRNA COVID-19 vaccines, according to a study published online May 25 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 26, 2021 Category: Pharmaceuticals Source Type: news

COVID Vax Response Low in Immune-Mediated Inflammatory Diseases COVID Vax Response Low in Immune-Mediated Inflammatory Diseases
Patients who take methotrexate or rituximab seem to be especially vulnerable.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - May 26, 2021 Category: Infectious Diseases Tags: Rheumatology News Source Type: news

Common Immune Drug Methotrexate May Hamper Response to COVID-19 Vaccine
WEDNESDAY, May 26, 2021 -- A widely used medicine for autoimmune diseases may lower people's immune response to the Pfizer mRNA COVID-19 vaccine, a new study suggests. The drug, called methotrexate, is often given to patients with immune-mediated... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 26, 2021 Category: General Medicine Source Type: news

Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn ’s Disease
SPRING HOUSE, PENNSYLVANIA, May 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA® (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),1-4including data from the SEAVUE study, the first head-to-head study of biologic therapies in patients with CD, presented in a Clinical Science Late-Breaking Abstract Plenary session.1 SEAVUE data showed treatment with STELARA demonstrated high rates of clinical remission, corticosteroid-free remission, clinical response and endoscopic response through one year in biologic-naïve p...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

High-Dose Methotrexate of No CNS Benefit in High-Risk DLBCL High-Dose Methotrexate of No CNS Benefit in High-Risk DLBCL
Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have a greater than 10% risk of central nervous system (CNS) relapse.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 19, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Some Should Stop Methotrexate for 2 Weeks After J & J Vaccine Some Should Stop Methotrexate for 2 Weeks After J & J Vaccine
The National Psoriasis Foundation COVID-19 Task Force now recommends that certain patients on methotrexate consider stopping the drug for 2 weeks after receiving the Johnson& Johnson COVID-19 vaccine.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - April 1, 2021 Category: Dermatology Tags: Dermatology News Source Type: news

SARS-CoV-2 hijacks two key metabolic pathways to rapidly replicate in host cells
(Brigham and Women's Hospital) Researchers studying cultured cells shortly after infecting them with SARS-CoV-2, now have more insight into the metabolic pathways co-opted by the virus. The findings highlight the potential therapeutic benefit of drugs such as methotrexate, which inhibit folate and one-carbon metabolic pathways appropriated by the virus. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 15, 2021 Category: Infectious Diseases Source Type: news

Hepatotoxicity Risk Differs Between Psoriasis, PsA, and RA Patients Hepatotoxicity Risk Differs Between Psoriasis, PsA, and RA Patients
Patients taking methotrexate for psoriasis or psoriatic arthritis were at a higher risk of developing liver disease than were patients with rheumatoid arthritis on methotrexate.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - February 26, 2021 Category: Rheumatology Tags: Rheumatology News Source Type: news

MTX Decreases Tenofovir Exposure in ART-Suppressed HIV MTX Decreases Tenofovir Exposure in ART-Suppressed HIV
A new study finds that methotrexate may alter tenofovir exposure among virally suppressed people living with HIV. Does this warrant a change in dosing during the co-administration of these drugs?JAIDS: Journal of Acquired Immune Deficiency Syndromes (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - November 30, 2020 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

RA Remission? Stop Methotrexate, Keep Etanercept RA Remission? Stop Methotrexate, Keep Etanercept
In patients with RA whose disease is well controlled by methotrexate and etanercept, withdrawal of methotrexate led to long-term outcomes that were nearly as good as continuation of combination therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 24, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news

After Methotrexate Failure, Is JAK Inhibitor or Biologic Next? After Methotrexate Failure, Is JAK Inhibitor or Biologic Next?
What is the next step in treatment after a person with rheumatoid arthritis fails to adequately respond to methotrexate -- a Janus kinase inhibitor or a biologic?Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 23, 2020 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news

Methotrexate and HCQ Split on Cardiovascular Outcomes in RA Methotrexate and HCQ Split on Cardiovascular Outcomes in RA
No significant differences in major adverse cardiovascular events emerged between methotrexate and hydroxychloroquine treatment in a comparison of adults 65 years or older with rheumatoid arthritis.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 13, 2020 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news

Proposed RA Guidelines: Maximize Methotrexate Before Switching Proposed RA Guidelines: Maximize Methotrexate Before Switching
Use methotrexate aggressively before switching to a biologic or JAK inhibitor, authors propose in guidelines, updated from 2015, for rheumatoid arthritis. They also urge moving away from prednisone.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 9, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Methotrexate Users Need Tuberculosis Tests in High-TB Areas Methotrexate Users Need Tuberculosis Tests in High-TB Areas
Those taking corticosteroids or other immunosuppressants are at particularly high risk, a systematic review of literature finds.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 7, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news

New RA guideline emphasizes maximizing methotrexate and biologics, minimizing steroids
(American College of Rheumatology) The American College of Rheumatology (ACR) will preview its 2020 Guideline for the Management of Rheumatoid Arthritis (RA) at ACR Convergence, the ACR's annual meeting. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 6, 2020 Category: International Medicine & Public Health Source Type: news

SIMPONI ARIA ® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Glo...
Source: Johnson and Johnson - September 30, 2020 Category: Pharmaceuticals Source Type: news

Tocilizumab ± methotrexate not a cost-effective option in early RA
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 31, 2020 Category: Drugs & Pharmacology Source Type: news

Methotrexate Treat-and-Extend Tested for Vitreoretinopathy Methotrexate Treat-and-Extend Tested for Vitreoretinopathy
A methotrexate protocol that involves treat-and-extend dosing can be used to successfully treat proliferative vitreoretinopathy, a case series shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 27, 2020 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Intraventricular Methotrexate Betters Survival in Medulloblastoma Intraventricular Methotrexate Betters Survival in Medulloblastoma
Intraventricular methotrexate and systemic chemotherapy produced favorable survival outcomes in patients with desmoplastic medulloblastoma and medulloblastoma with extensive nodularity in new study.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 20, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

TREMFYA ® (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
HORSHAM, PA, July 14, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.[1],[2] TREMFYA is the first treatment approved for active PsA that selectively inhibits interleukin (IL)-23, a naturally occurring cytokine that is involved in normal inflammatory and immune responses associated with the symptoms of PsA. The safety and efficacy of TREMFYA in PsA have b...
Source: Johnson and Johnson - July 14, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Rheumatoid Arthritis Treatment Doesn't Harm Lungs: Study
MONDAY, July 13, 2020 -- Treatment with the immunosuppressant methotrexate does not raise the risk of lung disease among rheumatoid arthritis patients, two new studies claim. At least 5% to 10% of rheumatoid arthritis (RA) patients develop... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 13, 2020 Category: General Medicine Source Type: news

What Causes Early Pregnancy Vaginal Bleeding?
Discussion Pregnancy complications in early pregnancy range from mild to severe. They can include nausea and emesis which often is treated symptomatically, but can cause hyperemesis gravidarum and need hospitalization for intravenous fluids. Mild cramping and slight spotting are not uncommon. Some type of pregnancy bleeding is common with 20-40% of women experiencing it. Women who have early vaginal bleeding have a higher risk of later pregnancy complications. Pregnancy in adolescents is about 10% of all pregnancies. Adolescent pregnancy can be associated with various problems including higher rates of threatened aborti...
Source: PediatricEducation.org - July 13, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Upadacitinib Beats Methotrexate in Early Rheumatoid Arthritis
WEDNESDAY, July 8, 2020 -- Upadacitinib monotherapy results in improved outcomes versus methotrexate for patients with predominantly early rheumatoid arthritis, according to a study published online July 8 in Arthritis& Rheumatology. Ronald van... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 8, 2020 Category: Pharmaceuticals Source Type: news

Started Early, Drug Combo Eases Fatigue of Rheumatoid Arthritis: Study
FRIDAY, June 26, 2020 -- Early and intensive treatment with methotrexate and prednisone can ease fatigue in people with rheumatoid arthritis (RA), according to a new study. RA causes chronically inflamed joints and that inflammation can lead to... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 26, 2020 Category: General Medicine Source Type: news

Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
SPRING HOUSE, PENNSYLVANIA, June 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today its decision to discontinue the Phase 3 LOTUS study of STELARA® (ustekinumab) in Systemic Lupus Erythematosus (SLE) due to lack of efficacy in SLE.The decision is based on data from a pre-planned interim efficacy analysis. Interim safety findings were consistent with the known safety profile of STELARA, and no new safety signals were identified. Investigators, study participants and health authorities have been informed of the decision. The company intends to thoroughly analyze the totality of...
Source: Johnson and Johnson - June 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Mesothelioma Chemoperfusion Trial Shows Impressive Results
Study statistics show the benefits of the novel transarterial chemoperfusion treatment being used successfully at the Moffitt Cancer Center in Tampa for patients with relapsed pleural mesothelioma. Russell Lamkins — working on the roof of a neighbor’s house — shows them even better. He is living proof. This latest mesothelioma treatment has potential. Lamkins, 73, was first diagnosed with mesothelioma in 2014. He was the second patient to enroll in the mesothelioma clinical trial in March 2016, soon after standard-of-care chemotherapy and immunotherapy had failed him. “At that point, I had no choice...
Source: Asbestos and Mesothelioma News - June 22, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

No Link Between Methotrexate, Interstitial Lung Disease in RA No Link Between Methotrexate, Interstitial Lung Disease in RA
Patients with rheumatoid arthritis are at elevated risk for interstitial lung disease, but methotrexate does not accentuate that risk and may be protective, new data show.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 11, 2020 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

TNF Inhibitor Plus Methotrexate Surpassed Monotherapy in PsA TNF Inhibitor Plus Methotrexate Surpassed Monotherapy in PsA
The addition of a TNF inhibitor to the treatment regimen of patients with psoriatic arthritis (PsA) improves the achievement of minimal disease activity, new research shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 10, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Janssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA ® (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
HORSHAM, PA, April 24, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI ARIA® (golimumab) for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA), in patients two years of age and older in combination with methotrexate. If approved for these indications, SIMPONI ARIA would be the first anti-tumor necrosis factor (TNF)-alpha biologic agent administered by intravenous infusion av...
Source: Johnson and Johnson - April 24, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

IBD and COVID-19: Hold Certain Meds, AGA Advises
Patients with inflammatory bowel disease (IBD) who develop COVID-19 should stop taking thiopurines, methotrexate, tofacitinib, and biological therapies during the viral illness, according to the AGA. (Source: WebMD Health)
Source: WebMD Health - April 14, 2020 Category: Consumer Health News Source Type: news

Toxicity Due to Combination of Leflunomide and Methotrexate: Toxicity Due to Combination of Leflunomide and Methotrexate:
Therapy with methotrexate and leflunomide in a patient with active rheumatoid arthritis produced an unusual combination of drug-induced thrombotic microangiopathy and liver injury.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 14, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Methotrexate Treatment of Chronic Chikungunya Arthritis Methotrexate Treatment of Chronic Chikungunya Arthritis
Is methotrexate a safe and effective therapeutic option for chikungunya-related chronic arthritis? The authors report their experience with this treatment.Journal of Clinical Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 14, 2020 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

IBD and COVID-19: Hold Certain Meds, AGA Advises IBD and COVID-19: Hold Certain Meds, AGA Advises
Patients with inflammatory bowel disease (IBD) who develop COVID-19 should stop taking thiopurines, methotrexate, tofacitinib, and biological therapies during the viral illness, according to the AGA.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - April 14, 2020 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Methotrexate vs curettage for low-risk gestational trophoblastic neoplasia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 31, 2020 Category: Drugs & Pharmacology Source Type: news